Sertindole

$58$424

Products Details

Product Description

– Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3].

Web ID

– HY-14543

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C24H26ClFN4O

References

– [1]David Murdoch, et al. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55.|[2]Wei Zhang, et al. Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases. Sci Rep. 2018 Oct 25;8(1):15753.|[3]Mario F Juruena, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85.

CAS Number

– 106516-24-9

Molecular Weight

– 440.94

Compound Purity

– 99.75

SMILES

– FC1=CC=C(N2C3=CC=C(Cl)C=C3C(C4CCN(CCN5CCNC5=O)CC4)=C2)C=C1

Clinical Information

– Launched

Research Area

– Neurological Disease; Cancer

Solubility

– DMSO : 25 mg/mL (ultrasonic)

Target

– 5-HT Receptor;Adrenergic Receptor;Autophagy;Dopamine Receptor

Isoform

– 5-HT2 Receptor

Pathway

– Autophagy;GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=